<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953560</url>
  </required_header>
  <id_info>
    <org_study_id>0034667956480</org_study_id>
    <nct_id>NCT03953560</nct_id>
  </id_info>
  <brief_title>Symptom-related Screening for Early Detection of CTEPH.</brief_title>
  <official_title>Symptom-related Screening Program Following Pulmonary Embolism for Early Detection of Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luis Jara-Palomares, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sociedad Española de Neumología y Cirugía Torácica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospitales Universitarios Virgen del Rocío</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Routine screening for Chronic thromboembolic pulmonary hypertension (CTEPH) i after PE is not&#xD;
      supported by current evidence and guidelines.&#xD;
&#xD;
      This study aims to evaluate if a screening program for patients with acute PE based on&#xD;
      telephone monitoring of symptoms and further examination if only symptomatic patients could&#xD;
      help an early detection of CTEPH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic thromboembolic pulmonary hypertension (CTEPH) is a long-term complication following&#xD;
      an acute or silent pulmonary embolism (PE). A history of acute PE was reported in 75% of&#xD;
      CTEPH patients. Nevertheless, incidence of CTEPH after a confirmed acute PE vary widely&#xD;
      depending of the studies, with estimated incidence from 0.5 to 4%. Performing a follow-up&#xD;
      examination of patients diagnosed with acute PE regardless of persisting symptoms and using&#xD;
      all available technical procedures is not cost-effective. As a consequence, routine screening&#xD;
      for CTEPH after PE is not supported by current evidence and guidelines.&#xD;
&#xD;
      CTEPH is a very disabling and mortal disease, although it is a potential curable disease.&#xD;
      However, delayed diagnosis and misdiagnosis is common. Patients are frequently diagnosed with&#xD;
      CTEPH at advanced stages of the disease leading to worse clinical outcomes. Early diagnosis&#xD;
      of CTEPH is essential, as delay in diagnosis may be associated with a worse prognosis, higher&#xD;
      perioperative mortality and inoperable diseases stages. Overall, evidence from various&#xD;
      sources suggests that early detection and treatment of CTEPH is advantageous in achieving&#xD;
      favorable clinical outcomes. Therefore, there is an important unmet need for early diagnosing&#xD;
      this disease.&#xD;
&#xD;
      Focusing diagnostic procedures only on symptomatic patients may be a practical approach for&#xD;
      detecting relevant CTEPH.&#xD;
&#xD;
      This study aims to evaluate if a screening program for patients with acute PE based on&#xD;
      telephone monitoring of symptoms and further examination if only symptomatic patients could&#xD;
      help an early detection of CTEPH.&#xD;
&#xD;
      Objectives&#xD;
&#xD;
        -  Primary outcome: To estimate the impact of an easy and simple strategy to identify&#xD;
           CTEPH.&#xD;
&#xD;
        -  Secondary outcomes:&#xD;
&#xD;
             -  To identify patients with CTED after PE&#xD;
&#xD;
             -  To obtain external validation from scores to identify patients at risk to develop&#xD;
                CTEPH&#xD;
&#xD;
             -  To develop new score to identify high risk population to develop CTEPH&#xD;
&#xD;
      Hypothesis Conceptual hypothesis: The use of a strategy to detect CTEPH will increase number&#xD;
      of patients diagnosed of pulmonary hypertension.&#xD;
&#xD;
      Operational hypothesis: The use of a strategy to detect CTEPH will increase in a 200% the&#xD;
      number of patients diagnosed with CTEPH.&#xD;
&#xD;
      Design Cohorts study in consecutive patients with objectively confirmed PE.&#xD;
&#xD;
      Specialists implied Internal medicine, Pulmonologist, Hematologist from 20 hospitals.&#xD;
&#xD;
      Inclusion criteria: 1) Age &gt; 18 year 2) Objectively confirmed diagnosis of acute PE by&#xD;
      multidetector CT, V/Q lung scan, or selective pulmonary angiography, according to established&#xD;
      diagnostic criteria, with or without symptomatic DVT, 3) Ability of subject to understand the&#xD;
      character and consequences of the study, 4) informed consent of the subject. Exclusion&#xD;
      criteria: refused informed consent, inability to cooperation.&#xD;
&#xD;
      Intervention Investigator from each center will recover consecutive PE patients and collect&#xD;
      baseline, demographic and co-morbidities.&#xD;
&#xD;
      In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will&#xD;
      be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO modified scale&#xD;
      will be cited as outpatient to be evaluated&#xD;
&#xD;
      A written informed consent will be required all patients evaluated in consultant.&#xD;
&#xD;
      Imaging studies and right heart catheterization is the procedure agreeing with the standard&#xD;
      care according to current ESC/ERS Guidelines.&#xD;
&#xD;
      In all patients, the following tests will be performed:&#xD;
&#xD;
        1. Pulsioximetry.&#xD;
&#xD;
        2. Electrocardiogram.&#xD;
&#xD;
        3. Blood sample with determination of NT-ProBNP.&#xD;
&#xD;
        4. Echocardiography. Only an echocardiography indicative of PH warrants further evaluation&#xD;
&#xD;
        5. V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are&#xD;
           detected by VQ scan.&#xD;
&#xD;
        6. Right heart catheterization &amp; Pulmonary CT Scan are required for confirming the&#xD;
           diagnosis&#xD;
&#xD;
      The relationship of Doppler echocardiography-estimated PASP with right heart catheterization&#xD;
      (RHC)-measured PASP was examined using Spearman's correlation coefficients. The Bland-Altman&#xD;
      method was then used to assess the agreement between Doppler echocardiography-estimated and&#xD;
      RHC measured PASP. Doppler echocardiography-estimated PASP within +/- 10mmHg of the value&#xD;
      measured on RHC was considered accurate, consistent with the cutoffs used in other&#xD;
      publications.&#xD;
&#xD;
      Secondary outcome include number of patients with chronic thromboembolic disease (CTED),&#xD;
      described as chronic thromboembolic pulmonary vascular obstruction with normal resting&#xD;
      pulmonary artery pressures.&#xD;
&#xD;
      Treatment: No treatment required&#xD;
&#xD;
      Statistical Plans Sample size calculation We estimate CTEPH prevalence in reference group of&#xD;
      1%, and a prevalence of CTEPH in interventional group of 2.8%. With unilateral test, con&#xD;
      confidence level of 95%, statistic power of 80% and losses expected of 25%, we calculated a&#xD;
      final sample size of 947.&#xD;
&#xD;
      The investigators calculate that 16-20 centers in Spain are needed to recruit patients&#xD;
&#xD;
      Investigators will compare baseline characteristics of patients with and without CTEPH using&#xD;
      chi-square tests for categorical variables and non-parametric rank tests for continuous&#xD;
      variables. Cumulative incidence of CTEPH will be estimated using the Kaplan-Meier technique.&#xD;
&#xD;
      To do external validation of previous score to predict CTEPH discriminative power by&#xD;
      calculating the area under the receiver-operating characteristic (ROC) curve will be done,&#xD;
      performing a non-parametric test of the equality of the areas under the ROC curves.&#xD;
      Goodness-of-fit of the score points for each score in a logistic regression model using&#xD;
      Pearson's chi-square test.&#xD;
&#xD;
      Student's t test and X2 test (or Fisher's exact test where appropriate) will be used to&#xD;
      compare continuous or categorical variables, and multivariable analysis through a logistic&#xD;
      regression model using the Wald method (step back) to identify independent predictors for the&#xD;
      occurrence of CTEPH. Covariates entering in the model will be selected by a significance&#xD;
      level of p &lt;0.20 on univariable analysis, or by a well-known association reported in the&#xD;
      literature. Then, the investigators will build a prognostic score assigning points to each&#xD;
      independent variable according to regression coefficients β, rounding to the nearest integer.&#xD;
      The investigators will assign a risk score to each patient by adding up points for each&#xD;
      independent variable. Performance will be quantified in terms of calibration using the&#xD;
      Hosmer-Lemeshow test. Model discrimination will be assessed using the C-statistic. Internal&#xD;
      validity of the score will be confirmed using bootstrap analysis. For the statistical&#xD;
      analysis the investigators will use the IBM SPSS Statistics program (version 19; SPSS Inc.,&#xD;
      Chicago, IL), and a two-sided p&lt;0.05 was considered to be statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Design Cohorts study in consecutive patients with objectively confirmed PE.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new diagnosis of CTEPH</measure>
    <time_frame>Up 3 years after PE</time_frame>
    <description>New diagnosis of CTEPH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>External validation from score to identify patients at risk to develop CTEPH</measure>
    <time_frame>Up 3 years after PE</time_frame>
    <description>external validation from score (Klok FA et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2016)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derivation of a score to identify high risk population to develop CTEPH</measure>
    <time_frame>Up 3 years after PE</time_frame>
    <description>With variables assocciated to CTEPH investigators will obtain derivation and validation of a score to identify high risk population to develop CTEPH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Chronic Thromboembolic Disease (CTED) after PE</measure>
    <time_frame>Up 3 years after PE</time_frame>
    <description>Describe the number and clinical characteristics of patients with CTED after PE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">947</enrollment>
  <condition>CTEPH</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Symptoms and Signs</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.&#xD;
In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.&#xD;
In all patients, the following tests will be performed:&#xD;
Pulsioximetry.&#xD;
Electrocardiogram.&#xD;
Blood sample with determination of NT-ProBNP.&#xD;
Echocardiography. Only an echocardiography indicative of PH warrants further evaluation&#xD;
V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.&#xD;
Right heart catheterization &amp; Pulmonary CT Scan are required for confirming the diagnosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>dyspnea grade ≥ II according NYHA-WHO</intervention_name>
    <description>Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.&#xD;
In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated&#xD;
Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.&#xD;
In all patients, the following tests will be performed:&#xD;
Pulsioximetry.&#xD;
Electrocardiogram.&#xD;
Blood sample with determination of NT-ProBNP.&#xD;
Echocardiography. Only an echocardiography indicative of PH warrants further evaluation&#xD;
V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.&#xD;
Right heart catheterization &amp; Pulmonary CT Scan are required for confirming the diagnosis</description>
    <arm_group_label>Screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 year&#xD;
&#xD;
          2. Objectively confirmed diagnosis of acute PE by multidetector CT, V/Q lung scan, or&#xD;
             selective pulmonary angiography, according to established diagnostic criteria, with or&#xD;
             without symptomatic DVT,&#xD;
&#xD;
          3. Ability of subject to understand the character and consequences of the study,&#xD;
&#xD;
          4. informed consent of the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refused informed consent, inability to cooperation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Jara-Palomares, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Surgical Unit of Respiratory Diseases, Virgen del Rocio Hospital, CIBERES</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Jara-Palomares, MD</last_name>
    <phone>0034667956480</phone>
    <email>luisoneumo@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Bosco Lopez Saez, MD</last_name>
      <phone>0034956005000</phone>
      <email>juanbosco.lopez@gm.uca.es</email>
    </contact>
    <investigator>
      <last_name>Juan Bosco Lopez Saez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorcio Hospitalario Provincial de Castellón</name>
      <address>
        <city>Castellón De La Plana</city>
        <state>Castellon</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Luisa Peris Sifre, MD</last_name>
      <phone>0034964376000</phone>
      <email>perisifre@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Luisa Peris Sifre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao</name>
      <address>
        <city>Galdakao</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aitor Ballaz Quincoces</last_name>
      <phone>0034944007000</phone>
      <email>AITOR.BALLAZQUINCOCES@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Aitor Ballaz Quincoces</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia López Miguel</last_name>
      <phone>0034967597100</phone>
      <email>patricialopezmiguel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Patricia López Miguel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Riera Mestre, MD</last_name>
      <phone>0034932607500</phone>
      <email>ariera@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Antoni Riera Mestre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parc Sanitari Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Javier Marchena</last_name>
      <phone>0034936615208</phone>
      <email>pjmy1@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Pablo Javier Marchena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Luz</name>
      <address>
        <city>Cuenca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio Nieto Rodríguez, MD</last_name>
      <phone>0034969179900</phone>
      <email>joseanietor@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nieto Rodríguez Nieto Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Criado</last_name>
      <phone>0034625611471</phone>
      <email>juancriadogarcia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Criado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Baeza Martínez</last_name>
      <phone>0034966616900</phone>
      <email>baezamartinez.c@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Baeza Martínez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Dr. Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iria Francisco Albesa</last_name>
      <phone>0034972940200</phone>
      <email>ifrancisco.girona.ics@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>Iria Francisco Albesa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lerida</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Lumbierres Burgués</last_name>
      <phone>0034973248100</phone>
      <email>mlumbierres@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Marina Lumbierres Burgués</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Maria Pedrajas Navas, MD</last_name>
      <phone>0034913303000</phone>
      <email>jmaria1963@gmail.com</email>
    </contact>
    <investigator>
      <last_name>José Maria Pedrajas Navas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Covadonga Gómez Cuervo, MD</last_name>
      <phone>0034913908000</phone>
      <email>cova.gomez.cuervo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Covadonga Gómez Cuervo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Jara-Palomares, MD</last_name>
      <phone>0034667956480</phone>
      <phone_ext>635624</phone_ext>
      <email>luisoneumo@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone_ext>Jara-Palomares</phone_ext>
      <email>luisoneumo@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Jara-Palomares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Joan XXIII de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio Porras Ledantes</last_name>
      <phone>0034977295800</phone>
      <email>aporras.hj23.ics@gencat.cat</email>
    </contact>
    <investigator>
      <last_name>José Antonio Porras Ledantes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Aibar Arregui</last_name>
      <phone>0034976765700</phone>
      <email>miguel_a_a_a@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Miguel Ángel Aibar Arregui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Luis Jara-Palomares, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CTEPH</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Symptoms and Signs</keyword>
  <keyword>Dyspnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be included in RIETE registry. We will done all analyses prestablished and data collected could be used by RIETE investigators</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

